Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEC afatinib translational study after osimertinib resistance in EGFR-mutant non-squamous NSCLC
jRCTs071180013Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Genetic alterations analysis. Started Aug 2019; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180013.